Six-month treatment for drug-resistant tuberculosis
Part of Infections clinical trials.
This study tests a shorter six-month treatment for tuberculosis that is resistant to rifampicin, a common antibiotic. The goal is to make treatment easier and possibly safer while still being effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years of age or older.
- You have tuberculosis that is resistant to the drug rifampicin, which has been confirmed by a test or through close contact with someone who has this type of TB.
- You have not yet started treatment for this type of TB, or you started within the last 10 days.
- You weigh at least 30 kg (about 66 pounds).
- You are willing to have an HIV test, and if you are HIV-positive, you are on or starting HIV treatment soon.
- You do not have severe liver, kidney, or heart problems that would interfere with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This Phase 3 trial tests a shorter, all-pill (oral) treatment plan for people with rifampicin-resistant pulmonary tuberculosis. It aims to improve treatment while reducing the burden of therapy, using a plan tailored to the individual.
This study tests a 6-month treatment with four oral medicines (bedaquiline, delamanid, linezolid, and levofloxacin) for people whose TB is resistant to rifampin. The goal is to see if this all-pill combination is safe and effective in treating this difficult type of TB.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
This trial tests whether a higher dose of the antibiotic rifampicin can shorten tuberculosis treatment from 6 months to 4 months. If you have drug-sensitive TB, this could mean fewer months of medication and fewer side effects.
This trial tests whether a shorter treatment using the drug rifampicin is as good as the usual longer treatment for people with less severe tuberculosis (TB). If you join, you'd get a shorter course of pills, which might be more convenient and have fewer side effects.
Hear when a new Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.